Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05089149 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chronic Heart Failure - COngestion eValuation

Study acronym: CHF-COV
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Interventions: Blood sample retrieved for biological assessment and biobanking (Procedure), Cardiac, pulmonary, peritoneal, jugular, renal venous Doppler… to Blood sample retrieved for biological assessment and biobanking (Procedure), Cardiac, pulmonary, peritoneal, jugular, renal Doppler…v6
  2. Interventions: Blood sample retrieved for biological assessment and biobanking (Procedure), Cardiac, pulmonary, peritoneal, jugular and renal venous… to Blood sample retrieved for biological assessment and biobanking (Procedure), Cardiac, pulmonary, peritoneal, jugular, renal venous Doppler…
    • Secondary endpoints: 15 to 17
    • Eligibility criteria expanded, about 2 words
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Dec 15, 2028 to Dec 14, 2028
    • Study completion date: Jun 15, 2029 to Jun 14, 2029
    • Start date changed from estimate of Dec 15, 2021 to Dec 14, 2021
    • Site details revised at 2 of 2 sites
  5. Secondary endpoints revised (15)v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.
Trial Details
NCT Number NCT05089149
Lead Sponsor Pr. Nicolas GIRERD
Conditions
(from sponsor)		 Chronic Heart Failure
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov